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Abstract
Previous studies have shown that enteroviral RNA can be detected in blood at the onset of type 1 diabetes (T1D).
The infection may play a role in triggering T1D and genetic host factors may contribute to this process. We
investigated (1) whether enterovirus is present at the onset of T1D in peripheral blood mononuclear cells
(PBMC), plasma, throat, or stool, and (2) whether enteroviral presence is linked with HLA-DR type and=or
polymorphisms in melanoma differentiation-associated gene 5 (MDA5) and 20-50 oligoadenylate synthetase 1
(OAS1), factors of antiviral immunity. To this end, PBMC, plasma, throat, and stool samples from 10 T1D
patients and 20 unrelated controls were tested for the presence of enteroviruses (RT-PCR), for HLA-DR type, and
polymorphisms in MDA5 and OAS1. Enterovirus RNA was detected in PBMC of 4=10 T1D patients, but none of
20 controls. Plasma was positive in 2=10 T1D patients and none of 20 controls, suggesting that enteroviruses
found at the onset of T1D are mainly present in PBMC. All throat samples from positive T1D patients were virus-
negative and only 1 fecal sample was positive. The negative results for all throat and most stool samples argues
against acute infection. Enterovirus presence was linked with HLA-DR4, but not with polymorphisms in MDA5
or OAS1.
Introduction
Coxsackie B viruses and echoviruses, both belonging tothe human enterovirus B group, have for decades been
implicated as environmental factors in type 1 diabetes (T1D),
which is generally regarded as an autoimmune disease (re-
viewed in 13 and 24). Support for their role in T1D is deduced
from: (1) prospective cohort studies that showed that en-
terovirus infections coincide with onset of autoimmunity and
with clinical onset of T1D (13); (2) detection of enterovirus
RNA in blood of T1D patients (see below); and (3) detection of
enterovirus in islets of individuals with established T1D
(10,23,33). Thus enteroviruses may be involved in T1D via
various routes: indirectly, through triggering of autoimmu-
nity, or more directly, through infection of islets and de-
struction of b cells. It should be noted, however, that these two
processes are not necessarily mutually exclusive; they may
even be interrelated.
Enterovirus RNA has been found in blood by RT-PCR
at onset of disease in 20–75% of T1D patients (1,3,5,6,8,17,
18,32). Enterovirus has furthermore been found in autoanti-
body-positive (pre-diabetic) persons (15–17), and in patients
with established T1D (1,3), but not, or with a much lower
frequency, in matched healthy controls without predisposi-
tion for T1D or in T2D patients (1). So far, none of the studies
that detected viral RNA in the blood of T1D patients inves-
tigated the stage of infection, or whether a positive RT-PCR
result was due to early infection with virus excreted in the
throat, or due to convalescence with virus detectable in stool
only, which can last for up to 3 mo (4). Another possibility
1Department of Medical Microbiology, and 6Department of Tumor Immunology, Radboud University Nijmegen Medical Centre and
Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands.
2Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
3Department of Bloodtransfusion and Transplantation Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The
Netherlands.
4Diabeter, Center for Pediatric and Adolescent Diabetes Care and Research, Rotterdam, The Netherlands.
5Department of Pediatrics, Erasmus University Medical Centre, Rotterdam, The Netherlands.
VIRAL IMMUNOLOGY
Volume 23, Number 1, 2010
ª Mary Ann Liebert, Inc.
Pp. 99–104
DOI: 10.1089=vim.2009.0072
99
is that virus remains detectable beyond convalescence (stool-
negative). Taken together, this difference from unrelated
healthy people suggests that T1D patients and those at risk
for the disease are more susceptible to enteroviruses, or are
unable to clear the infection, both conditions that may be
involved in T1D.
Besides environmental factors, a strong genetic predispo-
sition is involved. HLA-DR3 and DR4 are major risk factors,
whereas DR2 is negatively associated with the disease (2,7,
20,22,29). Other genetic factors have also been associated
with T1D, and new associations are still being found, including
two recently identified single nucleotide polymorphisms
(SNPs) that are involved in antiviral immunity (11,26,28,30).
These factors, melanoma differentiation-associated gene 5
(MDA5) and 20-50 oligoadenylate synthetase 1 (OAS1), play an
important role in the innate defense against RNA viruses by
sensing or degrading enteroviral RNA, respectively. These
SNPs may thus provide a link between enteroviruses and T1D.
In this study we investigated (1) whether peripheral blood
mononuclear cells (PBMC) contain enteroviral RNA, (2) what
is the stage of infection, and (3) whether infection is linked to
particular risk alleles for HLA-DR and=or with SNPs in
MDA5 and OAS1.
Patients and Methods
Patients and control group
Patients and controls were from the Paediatric Clinics of
the Erasmus University Medical Centre, Rotterdam and the
Canisius-Wilhelmina Hospital, Nijmegen. Ten T1D patients
(5 males and 5 females) were included and samples were
collected within a month of diagnosis. Mean age of the patient
group was 9.7 y (range 5–14 y). For controls, a group of 20
hospitalized children (9 males and 10 females, 1 of whom for
which the gender was unknown) of the same age range with
non-endocrine disorders was included. Their mean age was
12.5 y (range 6–17 y). Samples from the T1D patients were
obtained between November 2003 and November 2004, and
from healthy controls in June 2004. Informed consent was
given by the parents, based on a study protocol that was
approved by the local ethical committees of the respective
hospitals.
Laboratory samples
The following samples were collected: (1) 5 mL of citrate
blood for isolation of plasma and PBMC, (2) 5 mL of clotted
blood for serum, (3) a throat swab in virus transport medium,
and (4) a fecal sample. PBMC were isolated as instructed by
the manufacturer (Becton and Dickinson, Erembodegem,
Belgium). After processing, all samples were flash frozen and
stored at –808C until use.
Virus detection
RNA was isolated from 200mL of plasma, the equivalent of
2105 PBMCs (isolated PBMCs dissolved in PBS), and stool
sample homogenates. For the in-house nested RT-PCR, RNA
extraction was done using the MagNaPure LC Isolation sta-
tion (Roche Applied Science, Mannheim, Germany). Ampli-
fication was performed in a nested PCR reaction as previously
described (9), as was real-time PCR (19). Real-time NASBA
(NucliSens EasyQ) was performed according to the manu-
facturer’s instructions (BioMe´rieux, Boxtel, The Netherlands).
The amplification techniques were regularly tested against
Quality Control for Molecular Diagnostics (QCMD) stan-
dards. An enterovirus-specific internal homologous control
RNA was included in each sample during the extraction to
monitor the NucliSens EasyQ and PCR procedures at the
individual sample level. This excludes false-negatives due to
inhibitory factors in the input samples, which may be present,
particularly in stool samples. The sensitivity of the methods is
at least 0.002–0.01 TCID50 for in-house nested RT-PCR and
real-time PCR, depending on the enterovirus strain tested.
NASBA is similarly or somewhat less sensitive than the PCR,
depending on the enterovirus strain.
Interferon-a detection
The amount of interferon-a (IFN-a) in the plasma samples
was determined using a commercial ELISA kit, product
number RDI-PB41110, from Research Diagnostics Inc. (Fitz-
gerald Industries International, North Acton, USA). The test
was performed according to the manufacturer’s instructions.
HLA typing
Total nucleic acids (NA) was isolated using MagNaPure
as described above. HLA typing was performed on RNase-
treated DNA using the lifecodes HLA-SSO typing kit (Tepnel,
Manchester, UK) according to manufacturer’s instructions and
EFI=ASHI guidelines for histocompatibility testing.
MDA5 and OAS1 single nucleotide
polymorphism typing
The MDA5 SNP tested was the A946T polymorphism
(rs1990760) described by Smyth et al. (26). The OAS1 SNP
tested was rs10774671, which is an A=G splice-site SNP
(11,27,28). SNPs in MDA5 and OAS1 were assessed by am-
plification of the relevant region, followed by sequencing of
the PCR product. From the sequence, the presence of the
SNP and homo- or heterozygosity was determined. Primers
are available upon request.
Results
Detection of enterovirus RNA in PBMC of T1D patients
Ten recently diagnosed T1D patients were tested by RT-
PCR (9), and compared with 20 healthy children of the same
age without known risk factors for T1D. PBMC and
plasma were tested separately. Four of the 10 T1D patients
(40%) were positive for enterovirus in their PBMC, and two
of them were also positive in plasma (Table 1). The outcome
was confirmed on separately isolated total NA by real-time
PCR (19), and by NASBA, an RNA-based amplification
technique (data not shown). Amplification of part of the
50UTR yielded a fragment that showed strong similarities to
viruses from the human enterovirus B group. Unfortunately,
attempts to amplify the variable region (VP1-2A) using de-
generate primers failed, making further typing of the en-
teroviruses impossible. None of the 20 children in the control
group were positive for enteroviral RNA in either PBMC or
plasma (Table 1). All controls were sampled in June 2004,
whereas T1D patients were sampled throughout the year.
Although this could have led to bias, there was no obvious
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tendency of the four positive patients to test positive in any
particular season, and only one of the four was sampled in
the ‘‘enterovirus season,’’ late summer and early autumn.
The virus-positive T1D patients were sampled in August,
November (2), and February.
Prolonged enterovirus infection in T1D patients
Little is known about the stage of enterovirus infection in
T1D patients that are enterovirus-positive at the onset of
disease. Therefore we investigated whether virus could be
detected in throat or stool samples, which may have given
some indication of the stage of infection. Throat and stool
samples were collected at the same time as the blood samples
were drawn. The samples were tested by RT-PCR (throat) or
virus isolation and NASBA (fecal samples). The throat
samples were invariably negative, as was virus isolation,
whereas enterovirus was detected by NASBA in only 1 of the
4 virus-positive patients, suggesting that the infections were
in a late stage or of prolonged duration (4) (Table 1).
Detection of IFN-a
In a previous study researchers found that T1D patients
have elevated levels of IFN-a in their blood, which correlated
with the presence of enterovirus (3). Using ELISA, we in-
vestigated whether the presence of viral RNA was linked to
increased IFN-a levels in the blood, but no association was
found (Table 1).
Enterovirus and genetic risk factors
The prolonged presence of viral RNA in PBMC of T1D
patients suggests some intrinsic susceptibility to enterovirus
infection or an inability to clear the infection. Some of the
genetic risk factors that predispose to T1D also play a role in
antiviral defense, and thus may be involved in aberrant
clearance of enteroviruses. Therefore we tested whether the
presence of viral RNA was linked with HLA-DR type and=or
with SNPs in either MDA5 or OAS1.
HLA typing was performed on DNA isolated from PBMC.
The T1D-predisposing HLA-DR4 and to a lesser extent DR3
were more abundant in the T1D population: 9 of the 10 (90%)
T1D patients had a DR3 and=or DR4 allele, versus 13 out of
20 (65%) in the control group (Table 1). The high-risk
DR3=DR4 or DR4=DR4 phenotype was found in 3 of 10
(30%) T1D patients: 2 of 4 (50%) virus-positive patients,
versus 1 of 6 (17%) virus-negative patients, but not in any of
the 20 controls. All virus-positive patients had a DR4 allele.
The MDA5 and OAS1 polymorphisms were assessed by
amplification of the region containing the SNPs, followed by
Table 1. Background Information and Enterovirus RNA Detection in T1D Patients and Controls
Patient Date of birth Gender HLA-DRB1 Plasma PBMC Feces Throat IFN-a
1 04-05-1998 M DRB1*04=DRB1*13 þ þ þ – <
2 11-05-1989 M DRB1*0301=DRB1*04 – – – – <
3 02-08-1992 M DRB1*01=DRB1*13 – – – – 13
4 30-05-1995 M DRB1*0301=DRB1*04 – þ – – <
5 22-03-1996 F DRB1*04=DRB1*15 – – – – <
6 29-11-1995 M DRB1*01=DRB1*0301 – – n.t. – <
7 31-08-1993 F DRB1*04=DRB1*10 – þ n.t. – <
8 03-03-1995 F DRB1*01=DRB1*04 – – – – <
9 11-07-1995 F DRB1*04=DRB1*08 – – – – n.t.
10 04-02-1993 F DRB1*04=DRB1*04 þ þ – – n.t.
Control Date of birth Gender HLA-DRB1 Plasma PBMC Feces Throat IFN-a
1 03-07-1998 F DRB1*14=DRB1*15 – – n.t. – <
2 06-03-1997 M DRB1*0301=DRB1*11 – – n.t. – >500
3 20-05-1989 F DRB1*04=DRB1*11 – – n.t. – <
4 15-08-1988 M DRB1*13=DRB1*14 – – n.t. – <
5 25-05-1992 F DRB1*04=DRB1*13 – – n.t. – <
6 01-02-1989 M DRB1*07=DRB1*07 – – n.t. – <
7 23-05-1995 M DRB1*01=DRB1*04 – – n.t. – <
8 29-09-1989 M DRB1*14=DRB1*14 – – n.t. – <
9 07-02-1996 M DRB1*04=DRB1*15 – – n.t. – <
10 29-01-1993 M DRB1*01=DRB1*13 – – n.t. – <
11 17-02-1997 ? DRB1*01=DRB1*04 – – n.t. – <
12 17-06-1991 F DRB1*04=DRB1*14 – – n.t. – <
13 27-03-1993 F DRB1*07=DRB1*13 – – n.t. – <
14 10-09-1989 M DRB1*04=DRB1*11 – – n.t. – 75
15 30-08-1993 F DRB1*01=DRB1*0301 – – n.t. – <
16 19-04-1989 F DRB1*01=DRB1*04 – – n.t. – <
17 08-01-1987 F DRB1*14=DRB1*15 – – n.t. – <
18 10-09-1988 F DRB1*0302=DRB1*07 – – n.t. – <
19 04-10-1988 M DRB1*04=DRB1*13 – – n.t. – <
20 15-03-1988 F DRB1*01=DRB1*0301 – – n.t. – <
Abbreviations: M, male; F, female; ?, gender unknown; þ, positive reaction; –,negative reaction; n.t., not tested.
Interferon-a (IFN-a) plasma levels given in pg=mL; detection threshold 10 pg=mL; <, less than the detection limit.
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sequencing of the PCR product. Smyth et al. found a higher
prevalence of AA and GA in MDA5 in T1D patients
(AAþGA 87.4% in T1D patients and 85.5% in controls) (26).
We found that the T1D-associated AA and GA genotypes in
MDA5 were present in 3 and 6 of 10 patients (90%) and in 5
and 12 of 20 controls (85%), respectively. Heterozygosity was
most prominent in virus-positive patients (3 of 4 or 75%)
(Table 2). The remaining virus-positive patient had an AA
genotype. Three out of six virus-negative patients (50%) had
a GA genotype, 2 (33%) had a GG genotype, and 1 (17%) an
AA genotype (Table 2). Thus no major differences were ob-
served in the MDA5 polymorphism between virus-positive
and virus-negative patients.
Field and colleagues reported an increased prevalence of
GG and GA in OAS1 in the T1D group (GGþGA 58.7% of
T1D patients, compared to 50.3% of controls) (11). However,
Smyth et al. did not find an increased prevalence of GG and
GA genotypes in T1D patients (27). We found that T1D-
associated GG and GA genotypes of OAS1 were present in 2
and 3 of 10 T1D patients (50%) and in 3 and 8 out of 20
controls (55%), respectively (Table 2). Thus no obvious dif-
ferences were observed between T1D patients and the con-
trol group. Remarkably, only 1 of 4 (25%) virus-positive
patients had a GG or GA genotype, compared to 4 out of 6
(67%) virus-negative T1D patients (Table 2). Ours was a
small sample, and future studies in which more T1D patients
are included are required to shed more light on the associ-
ation of MDA5 and OAS1 SNPs with T1D, and with the
presence of viral RNA in PBMCs of T1D patients.
Discussion
In this study we demonstrated the presence of enterovirus
RNA in the blood of 4 out of 10 T1D patients early after
onset. Viral RNA was mainly detected in PBMC, the throat
samples were negative, and only in 1 case was the stool also
positive. An HLA-DR4 allele was present in all enterovirus-
positive patients, yet no obvious link with polymorphisms in
MDA5 or OAS1 was found.
Four out of 10 T1D patients were found to be positive for
enterovirus RNA in PBMCs. We used very sensitive methods
for virus detection; levels as low as 0.002–0.01 TCID50 were
detectable with the PCR and NASBA tests we used, de-
pending on the enterovirus strain. All patient samples were
tested with two different PCRs and NASBA to confirm
the results. However, we cannot conclude that the 6 virus-
negative T1D patients had no RNA in their PBMCs, as their
levels may have been below the detection limit of the tests
we used.
The finding of viral RNA in the blood of T1D patients is in
accordance with results of previous studies (1,3,5,6,17,18,32).
In most studies, researchers tested for the presence of en-
teroviral RNA in whole blood, plasma, or serum samples. To
date, in only one study was the presence of enteroviral RNA
specifically sought in PBMCs of T1D patients (32). Our study
shows that viral RNA is mainly present in the fraction of
PBMCs, as only 2 out of 4 PBMC-positive patients were also
positive in plasma. This indicates that the PBMC fraction
may be the most important fraction to consider when
screening for enterovirus positivity in human blood. That
viral RNA was mainly detected in PBMCs suggests either
infection of cells of the immune system, or uptake of virus-
infected cells or cell-debris (e.g., by dendritic cells, as we
demonstrated in vitro [14]). Infection of immune cells versus
uptake of virus-containing material may have different
consequences for immune function (impairment versus im-
mune system activation). Whether and how altered immune
homeostasis in the blood may affect immune homeostasis in
the pancreas, thereby contributing to the development of
T1D, requires further investigation.
During the early phase of infection, enterovirus is excreted
in the throat and gastrointestinal tract. In this phase, the
virus can sometimes also be detected in blood, but this is
highly unusual, and occurs primarily during severe infec-
tions (12,31). We found no enterovirus RNA in the blood of
healthy controls, a finding that also corresponds with other
reports, in which no or very few controls were found to be
enterovirus RNA-positive in the blood (1,3,5,17,18). During
convalescence, virus is only detected in the stool, and fecal
excretion can last for up to 3 mo (4). All throat and 3 of 4
stool samples were negative in the 4 T1D patients that were
positive in PBMCs, arguing against acute infection. Whether
this indicates a late stage of infection, or even a prolonged
infection, remains to be determined.
The occurrence of prolonged enterovirus infection in T1D
patients has also been suggested by Oikarinen and co-
Table 2. SNP Genotypes of OAS1 and MDA5
Polymorphisms
Patient Virus MDA5 OAS1
1 þ GA AA
2 – GA GA
3 – GG GA
4 þ AA AA
5 – AA GG
6 – GA AA
7 þ GA GG
8 – GA GA
9 – AA AA
10 þ GA AA
Control Virus MDA5 OAS1
1 – GG AA
2 – AA GA
3 – GA GA
4 – GA GA
5 – AA GG
6 – AA GA
7 – GG GA
8 – AA AA
9 – GA GA
10 – GA AA
11 – GA GA
12 – GA AA
13 – GA AA
14 – GA GG
15 – GA AA
16 – AA GA
17 – GA AA
18 – GA AA
19 – GG GG
20 – GA AA
Abbreviations: þ, enterovirus-positive; –, enterovirus-negative.
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workers (21), who provided evidence for ongoing enteroviral
infection in the gut mucosa of T1D patients. Detection of
enterovirus antigens and RNA in pancreatic islets from T1D
patients also suggests inadequate clearance (10,23,33).
Assuming that T1D patients or individuals at risk for T1D
have delayed clearance of enteroviruses, the question arises
as to whether and which genetic factors predispose to it. We
selected genetic risk factors for T1D that play a role in anti-
viral defense and investigated their linkage with the presence
of virus. The most obvious risk factors are HLA-DR and
molecules of the IFN pathway. It was to be expected that an
association would be found with the well-known high-risk
alleles DR3=DR4 and DR4=DR4, but no link with one of
these phenotypes was found; DR4 was present in all 4 virus-
positive patients. In a previous study, researchers reported
impaired cellular immune reactivity against coxsackie B
virus 4 in T1D patients, but this was not associated with
either HLA-DR3 or HLA-DR4 (25). Published data are incon-
sistent with regard to HLA and virus positivity: Andreoletti
et al. found DR3=DR4 in 2 out of 6 virus-positive T1D pa-
tients and 3 carrying a DR3 allele (1), whereas Craig et al.
reported that DR3 was significantly less prevalent in virus-
positive T1D patients (6). Clearly, further studies are required
to address these associations, but it appears unlikely that a
link with viral presence will be found.
Among the other genetic risk factors, MDA5 and OAS1
are of great interest, because they are involved in the innate
response against RNA viruses, such as enteroviruses. No
major differences were found between the T1D patients and
controls, or between virus-positive and virus-negative T1D
patients. Again, a link here seems unlikely, but our sample
size was too small to say so definitively.
Conclusion
In conclusion, our data indicate that T1D patients may
have delayed enterovirus clearance, with virus detected
predominantly in PBMC. No obvious link was found with
polymorphisms in MDA5 or OAS1, yet HLA-DR4 was
present in all enterovirus-positive patients. Further studies
are required to elucidate the intriguing relationship between
enterovirus infection, genetic determinants of antiviral im-
munity, and the risk of acquiring T1D.
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